Clinical trials: Erythropoietin
Asphyxia
Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth
Erythropoietin (Epo) is a hormone normally found in the body that may protect brain cells from damage due to lack of oxygen. This study will evaluate the safety of high-dose Epo in infants who did not get enough oxygen during…
- Trial name
- NCT00491413
- Testing
- epoetin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Anemia, Leukemia, Lymphocytic, Chronic
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
The purpose of this study is to evaluate the effect of treatment with epoetin alfa versus placebo on the percentage of red blood cells in anemic patients with chronic lymphocytic (white blood cell) leukemia and its effect on the…
- Conditions
- Anemia, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Cancer
- Trial name
- NCT00270049
- Testing
- epoetin alfa
- Volunteers
- 195 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Kidney Disease, Chronic
A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)
This retrospective observational study will evaluate the hemoglobin levels in patients with renal anemia over 6 months treatment with Mircera (methoxy polyethylene glycol-epoetin beta).
- Trial name
- NCT01379963
- Where
- 17 sites in Greece
- Volunteers
- 780 people
- Sponsor
- Hoffmann-La Roche
Kidney Transplantation
Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation
The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury.
- Trial name
- NCT00425698
- Testing
- Recombinant erythropoietin alpha (rHuEPO alpha)
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Hannover Medical School
Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
Patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse, Anemia
- Trial name
- NCT00189371
- Testing
- paclitaxel, carboplatin, epoetin alpha
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- AGO Study Group
Cardiac Surgery
Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery
The administration of rhEPO on the one day before cardiac surgery will be effective to decrease the bleeding due to the surgery.
- Trial name
- NCT00939978
- Testing
- rhEPO
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Yonsei University
Breast Cancer, Anemia
Treatment for Patients Suffering From Anemia Due to Chemotherapy
The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in female breast cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia…
- Trial name
- NCT00120692
- Testing
- Darbepoetin Alfa, Recombinant Human Erythropoietin
- Sponsor
- Amgen
Anemia Associated With Chronic Kidney Disease
Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis
The goal of this study is to assess if patients can be retained on long-term vadadustat therapy (and thus potentially benefit from the favorable safety profile) by incorporating a phased transition from Epogen to three times per…
- Trial name
- VOTE (NCT07565701)
- Testing
- Epoetin alga (Epogen)/vadadustat
- Volunteers
- 100 people
- Sponsor
- Geoff Block
Chronic Renal Failure Related Anemia
Efficacy and Safety Study of GerEPO
The purpose of the study is to establish the equivalence of GerEpo with the standard treatment Eprex® for a treatment period of 12 weeks in patients on Hemodialysis with respect to hemoglobin response and to establish the…
- Trial name
- NCT00229099
- Testing
- GerEPO
- Where
- 32 sites in Malaysia
- Volunteers
- 270 people
- Sponsor
- Ministry of Health, Malaysia
Anemia, Neoplasm
A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy
The purpose of this study is to compare the effectiveness of early treatment of anemia with epoetin alfa (a glycoprotein that stimulates red blood cell production) or best standard anemia care on the need for blood transfusions…
- Trial name
- NCT00283465
- Testing
- Epoetin alfa
- Volunteers
- 316 people
- Sponsor
- Janssen-Cilag B.V.
Moyamoya Disease, Pediatrics
Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients
This study evaluates the effect of recombinant human erythropoietin (rHuEPO) on the neovascularization of pediatric moyamoya disease patients.
- Conditions
- Moyamoya Disease, Pediatrics, Cerebrovascular Disorders
- Trial name
- NCT03882060
- Testing
- erythropoietin, Normal saline
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Nephrology
Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to evaluate whether the efficacy of Epoetin alfa DT is equivalent to that of Epoetin alfa RB for the treatment of anemia in patients with CKD receiving hemodialysis
- Trial name
- NCT00146224
- Testing
- Epoetin alfa RB, Epoetin alfa DT
- Volunteers
- 420 people
- Sponsor
- Amgen
Myelodysplastic Syndromes
Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)
Chronic anemia is the symptom most frequently found at diagnosis in low risk myelodysplastic syndrome. It generates an increased rate of morbidity and mortality in this population of patients whose median age is high and the rate…
- Trial name
- EPO-QoL (NCT02428686)
- Testing
- Epoetin beta (NeoRecormon)
- Where
- 31 sites in France
- Volunteers
- 50 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Anemia
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
This study will evaluate the efficacy and safety of subcutaneous (SC) epoetin beta in anemic participants with breast cancer undergoing chemotherapy.
- Trial name
- NCT02761642
- Testing
- Epoetin Beta
- Where
- 27 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndrome (MDS)
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
Primary Outcome Measures: To evaluate the efficacy of treatment with Azacitidine in patients with transfusion-dependent, low risk International Prognostic Scoring System (IPSS) 0 int-1, Myelodysplastic Syndrome (MDS) without…
- Trial name
- ABRAZA (NCT01338337)
- Testing
- Azacitidine
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Asociación Andaluza de Hematología y Hemoterapia
Anemia, Chronic Kidney Disease
Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease
The purpose of this study is to evaluate the ability of peginesatide (AF37702) to increase and maintain increased hemoglobin levels in participants with chronic kidney disease (CKD) (either not on dialysis, receiving regular…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure, Pure Red Cell Aplasia
- Trial name
- NCT00314795
- Testing
- Peginesatide
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 22 people
- Sponsor
- Takeda
Anemia of Chronic Kidney Disease
Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease
Phase III, multicenter, randomized, open, controlled clinical trial. A study designed as phase III, in 120 patients with chronic renal failure in the pre-dialysis stage, evaluate efficacy and safety of Hemax PFS® (PFS: prefilled…
- Trial name
- NCT04036253
- Testing
- Erythropoietin alfa
- Where
- 11 sites in Argentina, Paraguay
- Volunteers
- 43 people
- Sponsor
- Bio Sidus SA
Chronic Renal Failure, Anemia
Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis
This study is designed to evaluate the hemoglobin response to Aranesp® (darbepoetin alfa) in black subjects (African-Americans) with chronic renal failure (CRF) receiving hemodialysis and to examine the safety profile.
- Trial name
- NCT00111995
- Testing
- Aranesp®
- Volunteers
- 400 people
- Sponsor
- Amgen
Erythropoietin Adverse Reaction
The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp
The aim of the study is to 1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how. 2.
- Trial name
- EPOASA (NCT04330729)
- Testing
- Acetylsalicylic acid
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Zealand University Hospital
Malnutrition
Effects of Early Short-term Intravenous Iron Supplements Combined EPO in Preterm Infants
There are wide variations in iron supplementation practices in NICU.Guidelines on pediatric Parenteral nutrition suggested the dose of 200μg/kg.d iron by parenteral nutrition.
- Trial name
- NCT02060851
- Testing
- standard PN, Vifor, Vifor and EPO
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Kunshan First People's Hospital Affiliated to Jiangsu University